Leukemia Exploration and Prevention Grant Program (LEAP)

About this funding opportunity

2X GIFT MATCH: Your gift will be doubled. Donate Now.

Back

Research We Fund: Extramural Discovery Science (EDS) Apply for a Research Grant

[x] - Grant Types

[x] - ACS Professor Award Arizona (AZ) Discovery Boost Grants (DBG) ASTRO-ACS Clinician Scientist Development Grant (CSDG) Clinician Scientist Development Grant (CSDG) Discovery Boost Grants (DBG) HEALED Gold Medal RFA To Support Mind-Body-Spirit Wellness in Cancer Survivors Institutional Research Grants Mission Boost Grants (MBG) Postdoctoral Fellowships Research Scholar Grants RFA: Extramural Discovery Science Accelerator Award RFA: Leukemia Exploration and Prevention Grant Program (LEAP) TheoryLab Collaborative (TLC) Grant RFA: Cancer Health Research Centers (CHERCs) RFA: Biology to Prevention Award (CRUK) RFA: ACS - Fanconi Cancer Foundation Discovery Boost Grant RFA: American Cancer Society Catalyst Awards RFA: American Cancer Society - Flatiron Real-World Data Impact Award RFA: Yosemite-American Cancer Society Award Extramural Grants Department Staff Contacts Definition of Research Areas FAQs: ACS Extramural Discovery Science and Grant Application Submissions Extramural Priority Research Areas Our Grant Process Summer 2026 Grant Cycle: Summary of Changes American Cancer Society Research Events EDS: Our Research Programs

[] - Career Growth and Research Excellence Program

[] - ACS Professor Cancer Detection and Experimental Therapeutics (PF-CDET) Institutional Research Grants (IRG) Cell Biology and Immunology (PF-CBI) Clinical and Population Sciences (PF-CPS) Molecular Biology and Biochemistry (PF-MBB) Biochemistry and Immunology of Cancer Program

[] - DNA Mechanisms in Cancer (DMC) PRC Immunology and Blood Cell Development (IBCD) PRC RNA Mechanisms in Cancer (RMC) PRC Tumor Biochemistry and Endocrinology (TBE) PRC Mission Boost Grants (MBG) PRC Cell Biology and Preclinical Cancer Research Program

[] - Cancer Cell Biology (CCB) PRC Cancer Detection and Progression (CDP) PRC Experimental Therapeutics (ET) PRC Metastasis and Microenvironment (MM) PRC Clinical and Population Sciences Program

[] - Cancer Prevention and Health Promotion (CPHP) PRC Treatment, Palliative Care, and Survivorship Research (CTPS) Etiology, Screening, and Early Detection (ESED) Healthcare Outcomes, Policy, and Systems Research (HOPS) Peer Review Committees (PRCs)

[] - Discovery Scientific Council Community Research Partner Participation American Cancer Society Professors Nobel Laureates and the American Cancer Society American Cancer Society-Jiler Professors & Fellows Conference RFA: Leukemia Exploration and Prevention Grant Program (LEAP) Background

The formation of cancer is orchestrated by a confluence of external, cell-nonautonomous, factors and internal, cell-autonomous, factors. Discovering medical interventions that can disrupt this complex interplay of factors is challenging but necessary.

In the bone marrow, the acquisition of somatic mutations in leukemia-associated genes, resulting in clonal mosaicism, is termed clonal hematopoiesis of indeterminant potential (CHIP). CHIP is unequivocally associated with hematologic malignancies (HMs) and, therefore, considered a precancerous condition.

While CHIP is common in the elderly (more than 10% of people aged 70 and older), the overall risk of malignant transformation is low. However, in high-risk populations, like those with germline predispositions to HM, CHIP rates are much higher, and the risk of HM development is significantly greater.

One such high-risk population includes people with _RUNX1_ familial platelet disorder ( _RUNX1_-FPD), a rare heritable disease caused by germline _RUNX1_ mutations. Individuals with _RUNX1_-FPD have a 35 to 50% lifetime risk of HM, with acute myeloid leukemia as the most common and second deadliest HM. Despite the established link between _RUNX1_-FPD and HMs, there remains a significant gap in understanding the cell-nonautonomous factors that contribute to clonal evolution and malignant…

Topic areas: Life Sciences and Health.

Funding amount

This grant provides Varies in funding.

Deadline

Applications are accepted on a rolling basis; there is no single fixed deadline.

Who can apply

This opportunity is open to the following applicant types:

• Not specified by the program.

Eligibility

The program did not publish a separate eligibility statement. See the official opportunity page for the full eligibility criteria.

Agency

Leukemia Exploration and Prevention Grant Program (LEAP) is administered by American Cancer Society (ACS), listed via American Cancer Society.